Track topics on Twitter Track topics that are important to you
The FDA has granted a breakthrough therapy designation for abatacept for the prevention of moderate-to-severe acute graft-versus-host disease in patients who have undergone hematopoietic stem cell transplants from unrelated donors.
Original Article: FDA Grants Abatacept Breakthrough Designation for Acute GVHDNEXT ARTICLE
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...